Scientific Opinion on the substantiation of a health claim related to a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006

EFSA Journal

Volumn 12, Issue 5, 2014, Pages

[No Author Info available]

Author keywords

Bifidobacterium longum LA 101; health claims; intestinal discomfort; Lactobacillus helveticus LA 102; Lactococcus lactis LA 103; Streptococcus thermophilus LA 104

Indexed keywords

EID: 85054523389     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2013.3658     Document Type: Article

References (5)

1. Denis S, Alric M, Holowacz S, Martin F, Rousseau V and Paul F, unpublished. Collaboration de Recherche No ERT 03/01 (suite de la collaboration No ERT02/02, Rapport final).
2. Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X and Marteau P, 2008. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroentérologie Clinique et Biologique, 32, 147–152.
3. Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ, Veldhuyzen van Zanten SJ and Design of Treatment Trials Committee, 2006. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology, 130, 1538–1551.
4. Kellow J, Lee OY, Chang FY, Thongsawat S, Mazlam MZ, Yuen H, Gwee KA, Bak YT, Jones J and Wagner A, 2003. An Asia-Pacific, double blind, placebo controlled randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut, 52, 671–676.
5. Müller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B and Ruegg P, 2001. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Alimentary Pharmacology and Therapeutics, 15, 1655–1666.